ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Chest X-Ray Produces Many False-Positive Results

January 27, 2006

COG’s Peter Adamson Has A Conversation With The Cancer Letter

March 15, 2013

RPR Grant To NABCO Does Not Support Advocacy, Firm Says

November 10, 1995

DCT Will Consider Planning, Center Core Supplemental, Program Project Grants In $5 Million Surgical Oncology Development Effort

October 10, 1980

Young Elected ACS President, Von eschenback Pres.-Elect.

November 9, 2001

NCI to Spend 40 Percent of Stimulus Funds On Contracts

June 26, 2009